Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

AstraZeneca PLC, consolidated balance sheet: assets

US$ in millions

	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Property, plant and equipment	6,010)	5,818)	6,089)	6,425)	6,957)
Goodwill	11,550)	9,981)	9,898)	9,862)	9,871)
Intangible assets	20,981)	16,047)	16,448)	10,980)	12,158)
Investments in joint ventures	59)	—)	—)	—)	—)
Other investments	502)	281)	199)	201)	211)
Derivative financial instruments	465)	365)	389)	342)	324)
Other receivables	1,112)	1,867)	352)	—)	—)
Deferred tax assets	1,219)	1,205)	1,111)	1,514)	1,475)
Non-current assets	41,898)	35,564)	34,486)	29,324)	30,996)
Inventories	1,960)	1,909)	2,061)	1,852)	1,682)
Trade receivables, less amounts provided for doubtful debts	4,762)	5,514)	5,696)	6,630)	6,247)
Other receivables	1,072)	794)	835)	1,237)	671)
Prepayments and accrued income	1,398)	1,571)	1,098)	887)	929)
Trade and other receivables	7,232)	7,879)	7,629)	8,754)	7,847)
Other investments	795)	796)	823)	4,248)	1,482)
Derivative financial instruments	21)	40)	31)	25)	9)
Income tax receivable	329)	494)	803)	1,056)	3,043)
Cash and cash equivalents	6,360)	9,217)	7,701)	7,571)	11,068)
Current assets	16,697)	20,335)	19,048)	23,506)	25,131)
Total assets	58,595)	55,899)	53,534)	52,830)	56,127)

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Property, plant and equipment	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	AstraZeneca PLC property, plant and equipment decreased from 2012 to 2013 but then increased from 2013 to 2014 not reaching 2012 level.
Non-current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	AstraZeneca PLC non-current assets increased from 2012 to 2013 and from 2013 to 2014.
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	AstraZeneca PLC current assets increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	AstraZeneca PLC total assets increased from 2012 to 2013 and from 2013 to 2014.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	AstraZeneca PLC inventories decreased from 2012 to 2013 but then slightly increased from 2013 to 2014.
Trade receivables, less amounts provided for doubtful debts	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	AstraZeneca PLC trade receivables, less amounts provided for doubtful debts decreased from 2012 to 2013 and from 2013 to 2014.
Other investments	Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.	AstraZeneca PLC other investments decreased from 2012 to 2013 and from 2013 to 2014.
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	AstraZeneca PLC cash and cash equivalents increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.

AstraZeneca PLC (NYSE:AZN)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items